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Abstract
Background: Overweight and obese persons are at risk of a number of medical conditions which
can lead to further morbidity and mortality. The primary objective of this study is to provide an
estimate of the incidence of each co-morbidity related to obesity and overweight using a meta-
analysis.
Methods: A literature search for the twenty co-morbidities identified in a preliminary search was
conducted in Medline and Embase (Jan 2007). Studies meeting the inclusion criteria (prospective
cohort studies of sufficient size reporting risk estimate based on the incidence of disease) were
extracted. Study-specific unadjusted relative risks (RRs) on the log scale comparing overweight
with normal and obese with normal were weighted by the inverse of their corresponding variances
to obtain a pooled RR with 95% confidence intervals (CI).
Results: A total of 89 relevant studies were identified. The review found evidence for 18 co-
morbidities which met the inclusion criteria. The meta-analysis determined statistically significant
associations for overweight with the incidence of type II diabetes, all cancers except esophageal
(female), pancreatic and prostate cancer, all cardiovascular diseases (except congestive heart
failure), asthma, gallbladder disease, osteoarthritis and chronic back pain. We noted the strongest
association between overweight defined by body mass index (BMI) and the incidence of type II
diabetes in females (RR = 3.92 (95% CI: 3.10–4.97)). Statistically significant associations with obesity
were found with the incidence of type II diabetes, all cancers except esophageal and prostate
cancer, all cardiovascular diseases, asthma, gallbladder disease, osteoarthritis and chronic back pain.
Obesity defined by BMI was also most strongly associated with the incidence of type II diabetes in
females (12.41 (9.03–17.06)).
Conclusion: Both overweight and obesity are associated with the incidence of multiple co-
morbidities including type II diabetes, cancer and cardiovascular diseases. Maintenance of a healthy
weight could be important in the prevention of the large disease burden in the future. Further
studies are needed to explore the biological mechanisms that link overweight and obesity with
these co-morbidities.
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Background
A substantial literature has emerged which has found that
overweight and obesity are major causes of co-morbidities
which can lead to further morbidity and mortality [1-3].
The related health care costs are substantial [4-6]. As the
number of associated co-morbidities continues to
increase, systematic reviews and meta-analysis are impor-
tant tools to summarize the findings and produce more
precise estimates of risk associated with overweight and
obesity.
The primary objective of this study is to provide a compre-
hensive review of the incidence of co-morbidities related
to obesity and overweight. We have identified a number
of recent systematic reviews and meta-analyses on type II
diabetes [7], cardiovascular diseases [8,9], cancer [10],
breast cancer [11,12], esophageal or cardia adenocarci-
noma [13], pancreatic cancer [14] and prostate cancer
[15]. The rationale for re-conducting a review is threefold.
Firstly, it has been reported that abdominal obesity,
defined by waist circumference (WC) measurement in
comparison to the more traditional obesity definition,
based on Body Mass Index (BMI) measurement, is an even
better predictor of many cardiovascular diseases and type
II diabetes [16-24]. However, most recent reviews have
only focused on obesity defined by BMI instead of WC.
For example, a recent meta-analysis study has compared
BMI and WC as risk factors for ischaemic heart disease and
stroke but it only included studies with population from
the Asia Pacific region [8]. Also, only meta-analysis stud-
ies on BMI and type II diabetes have been conducted [7].
Secondly, associating the incidence of co-morbidities with
overweight and obesity can be done in many ways since
there are many different definitions. For instance, many
previous reviews have combined studies that have found
the association with per unit change of BMI (kg/m2) and
WC (cm) measurements [7-9,11,14,15]. We are interested
in measuring the incidence by categorization of over-
weight and obesity defined by BMI and WC measure-
ments, which has not been the focus of a majority of
previous reviews.
Thirdly, the previous meta-analysis studies primarily
focused on individual co-morbidities and they were con-
ducted by different authors and using different search
strategies, inclusion criteria and analysis methods. Only
one recent meta-analysis study conducted by Katzmarzyk
and Janssen comprehensively estimated the incidence of
eight different chronic diseases associated with obesity
[5]. An objective of this review is to apply a consistent
methodology across all relevant co-morbidities. This ena-
bles us to compare the number of studies and size of effect
across all co-morbidities.
Methods
Exposure variables
The definition for overweight is having a BMI greater than
or equal to 25 kg/m2 and below 30 kg/m2. The definition
for obesity is having a BMI greater than or equal to 30 kg/
m2 [25,26]. According to the World Health Organization
(WHO), the definition for abdominally overweight or
obesity is a WC of greater than or equal to 80 cm and 88
cm, respectively, for females, and 94 cm and 102 cm,
respectively, for males [25,26].
Disease outcomes
Possible co-morbidities of overweight and obesity were
identified from a preliminary search reviewed by an eating
disorder and obesity expert and a review of previous sys-
tematic reviews [1-3]. We also reviewed the leading causes
of global burden of disease and included the diseases
reported with burden attributable to overweight and obes-
ity [27]. Twenty co-morbidities were initially included in
this analysis: cancer (kidney, colorectal, prostate, ovarian,
uterine/endometrial, esophageal, pancreatic, and post-
menopausal breast), type II diabetes, cardiovascular dis-
ease risk (hypertension, coronary artery disease, conges-
tive heart failure, pulmonary embolism, stroke,
dislipidaemia), gallbladder disease, chronic back pain,
osteoarthritis, asthma, and sleep apnea.
Literature review
A literature search was conducted using the search terms:
'Incidence, Prevalence, Risk, Risk Factors, Cohort Studies,
Longitudinal Studies, Follow-up Studies, or Prospective
Studies' in combination with 'Adipose Tissue, Obesity,
Body Mass Index, or Body Composition' (all "exploded").
These same search terms were applied to each co-morbid-
ity (also "exploded") for both Medline and Embase search
engines to retrieve all potentially relevant English articles
(until January, 2007). We also searched ISI Web of Sci-
ence, Google Scholar, and the bibliographies of retrieved
articles.
The articles obtained from the literature search were then
evaluated according to criteria set out in Figure 1. Criteria
for inclusion were: prospective cohort study of the general
population of a Western country (countries in Europe or
North America, Australia or New Zealand), relevant out-
comes, a sample size of at least 200 subjects, and risk esti-
mate based on the incidence of disease instead of the
mortality rate of disease. For large cohorts with multiple
articles meeting the defined criteria, the most recent article
or the article with the most usable information was used.
Studies were excluded if they did not provide enough data
to allow calculation of unadjusted relative risks (RRs)
with 95% confidence intervals (CI) for the overweight and
obese groups compared to the normal group. Data
extracted for study characteristics included study design,BMC Public Health 2009, 9:88 http://www.biomedcentral.com/1471-2458/9/88
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country, cohort name, duration of follow-up, number of
patients in each study group, age range, gender and eth-
nicity. Ascertainment of exposure and outcome variables
was also recorded. The literature search was conducted by
ZA, the decisions on inclusion and exclusion were made
by ZA, NB, DPG, CLB and the data were extracted by ZA
and DPG.
Meta-analysis
RRs were measured by incidence rate ratios (IRRs) when
person-time data were available and by the ratios of pro-
portions (RR-Ps) when person-time data were not availa-
ble. Study-specific unadjusted RRs on the log scale
comparing overweight with normal and obese with nor-
mal were weighted by the inverse of their corresponding
variances to obtain a pooled RR with 95% CIs. We used
the random-effects model to estimate the pooled RR using
the maximum likelihood estimation method [28]. The Q
statistic was also calculated to assess the homogeneity of
RRs (log scale) [28]. Potential publication bias was visu-
ally inspected by funnel plots and tested by asymmetry
tests [29,30]; however it was performed only on those
meta-analyses which included sufficient number of stud-
ies (N>5). We also did various sensitivity analyses strati-
fied on the length of follow-up, age criteria and country to
examine the robustness of the results.
WC measurements were considered to be the better risk
predictor for some co-morbidities such as diabetes, hyper-
tension, coronary artery disease, congestive heart failure,
stroke and gallbladder disease [16-24]. Therefore, when
the RRs based on WC measurements for these co-morbid-
ities were available, they were pooled separately from
those based on BMI and used as the final RRs for these co-
morbidities. When both IRR and RR-P estimates were
available, both estimates were presented. Final results of
RRs were selected based on the number of pooled studies,
the duration of study follow-up and the sample size of
included studies
Results
A total of 89 relevant and unique studies were identified;
several studies featured for more than one co-morbidities.
Of the 20 co-morbidities, 18 were identified to have at
least one study meeting the inclusion criteria. Some stud-
ies were applicable to more than one co-morbidity. No
studies were found for dislipidaemia and sleep apnea. The
total numbers of studies included for each co-morbidity
varied from 1 to 14. Reasons for exclusion are given in
Table 1.
The majority of the studies were conducted in US (55%)
and in European countries (40%). Study characteristics
such as age criteria, study follow-up, ascertainment of
exposure and outcome variables were reported by the
majority of the studies. However, only a small number of
studies reported sample ethnicity and of those, the major-
ity was US studies. Among those US studies, one study
(endometrial cancer) was about the black women [31]
while for the remaining US studies, the proportion of
whites ranged from 81% to 95%. The mean duration of
study follow-up was 12.5 (SD = 7.2) years. Over half of
the studies (53%) were longer than 10 years while less
than 10% of the studies were shorter than 5 years. BMI
and WC measurements were clinically measured on 43%
of the studies and were self-reported on 56% of the studies
while one study did not provide such information.
Regarding the ascertainment of cases, 43 (48%) studies
identified cases from registry, database centre or clinical
evaluation; 34 (38%) studies were based on subject self-
reported information with some kind of confirmation
method such as medical records review; 6 studies were
based on medical records review and 5 studies (4 for
asthma and 1 for type-2 diabetes) were relying on self-
reported information alone. Note that cancer cases were
identified from cancer registry/database on 66% of the
studies.
Table 2 summarized our final results. Figures 2 to 18 pre-
sented the detailed results including study-specific and
pooled estimates. Results from the meta-analysis were
summarized in the following sections for each co-morbid-
ity.
Flowchart of article distribution for all diseases Figure 1
Flowchart of article distribution for all diseases.
Potentially relevant articles identified 
through Medline and Embase 
searches: n = A 
Articles excluded based on title and abstract 
review: n = B 
- Not prospective cohort: n = B (i) 
- Non-generalizable population: n = B (ii) 
- Irrelevant subject matter:  n = B (iii) 
- Drug or treatment: n = B (iv) 
- Food and nutrition: n = B (v) 
- Review article: n = B (vi) 
- Duplicate: n = B (vii)
Articles ordered for more detailed 
review: n = C 
Articles excluded after detailed review: n = D 
- Population not generalizable: n = D (i) 
- Mortality rates used: n = D (ii) 
- Study too small: n = D (iii) 
 
Articles meeting inclusion criteria and 
information extracted for meta-
analysis: n = E 
Articles included in final meta-
analysis calculations: n = G 
 
Articles not amenable to meta-analysis: n = F 
- Required information not provided: n = F (i) 
- Same cohort already used: n = F (ii) BMC Public Health 2009, 9:88 http://www.biomedcentral.com/1471-2458/9/88
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Breast cancer
In total, 14 studies were identified for post menopausal
breast cancer (Figure 2) [19,32-44]. The pooled IRRs [95%
CI] across categories of WC were 1.13 [1.01–1.07] for
overweight and 1.30 [1.17–1.44] for obesity while across
categories of BMI the IRRs were 1.08 [1.03–1.14] for over-
weight and 1.13 [1.05–1.22] for obesity.
Endometrial cancer
In total, 10 studies were identified to meet the inclusion
criteria for endometrial cancer (Figure 3)
[19,31,35,36,42,45-49]. The study on the US black
women was not included in the final result as it showed
systematic difference from other studies mainly on Cauca-
sian population [31]. The pooled IRRs [95% CI] across
categories of WC were 1.15 [1.02–1.30] for overweight
and 1.42 [0.80–2.49] for obesity while across categories of
BMI IRRs were 1.53 [1.45–1.61] for overweight and 3.22
[2.91–3.56] for obesity.
Ovarian cancer
In total, 9 studies were identified for ovarian cancer (Fig-
ure 4) [19,35,36,42,45,50-53]. The single IRR [95% CI]
across categories of WC were 0.61 [0.35–1.08] for over-
weight and 1.35 [0.95–1.93] for obesity while pooled
IRRs estimates across categories of BMI were 1.18 [1.12–
1.23] for overweight and 1.28 [1.20–1.36] for obesity.
Table 1: Article distribution for all diseases (see Figure 1 for explanation)
Diseases A B B
(i)
B
(ii)
B
(iii)
B
(iv)
B
(v)
B
(vi)
B
(vii)
CD D
(i)
D
(ii)
D
(iii)
EFF
(i)
F
(ii)
G
Type II Diabetes 8142 8075 6687 18 1216 20 28 18 88 67 37 17 6 14 30 21 19 2 9
Colorectal cancer 445 413 5 22 261 8 42 57 18 32 6 2 2 2 26 14 14 0 12
Kidney cancer 2661 2606 55 12 2010 51 50 127 301 55 43 16 18 9 12 7 7 0 5
Prostate cancer 491 462 28 1 258 0 37 52 86 29 14 5 9 0 15 7 6 1 8
Breast cancer 2755 2682 145 18 1793 19 110 195 402 73 43 6 34 3 30 16 13 3 14
Ovarian cancer 241 228 23 1 143 0 10 13 38 13 4 1 3 0 9 0 0 0 9
Endometrial cancer 1249 1192 103 17 729 8 30 105 200 57 41 27 3 11 16 6 5 1 10
Pancreatic cancer 155 131 5 0 81 0 14 7 24 24 15 5 10 0 9 3 2 1 6
Esophageal cancer 230 222 23 0 103 2 13 34 47 8 6 4 2 0 2 1 1 0 1
Hypertension 2882 2773 59 55 2256 53 78 81 191 109 88 23 53 12 21 17 17 0 4
CAD 3041 2966 96 17 2202 42 66 82 461 75 50 10 27 13 25 14 11 3 11
CHF 625 586 10 5 418 6 1 41 105 39 25 0 14 11 14 10 9 1 4
PE 527 497 48 13 321 1 0 24 90 30 11 3 3 5 19 18 18 0 1
Stroke 2783 2755 172 29 1747 17 24 234 532 28 17 6 5 6 11 4 4 0 7
Asthma 1408 1359 89 13 598 47 47 84 481 49 36 2 25 9 13 9 9 0 4
GD 319 305 29 9 175 0 7 32 53 14 5 0 2 3 9 5 5 0 4
OA 853 824 43 10 390 51 38 123 169 29 14 5 2 7 15 12 12 0 3
CBP 324 306 30 20 143 39 11 24 39 18 6 0 4 2 12 11 11 0 1
CAD: Coronary Artery Disease; CHF: Congestive Heart Failure; PE: Pulmonary Embolism; GD: Gallbladder Disease; OA: Osteoarthritis; CBP: 
Chronic Back PainBMC Public Health 2009, 9:88 http://www.biomedcentral.com/1471-2458/9/88
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Meta-analysis of studies for post menopausal breast cancer Figure 2
Meta-analysis of studies for post menopausal breast cancer. *Q-statistic(p-value); F-up is follow-up in years; square 
shape: study- and gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for endometrial cancer Figure 3
Meta-analysis of studies for endometrial cancer. *Q-statistic(p-value); **pre-menopause, square shape: study- and gen-
der- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for ovarian cancer Figure 4
Meta-analysis of studies for ovarian cancer. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gen-
der- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for colorectal cancer-females Figure 5
Meta-analysis of studies for colorectal cancer-females. *Q-statistic(p-value); F-up is follow-up in years; square shape: 
study- and gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for colorectal cancer-males Figure 6
Meta-analysis of studies for colorectal cancer-males. *Q-statistic(p-value); F-up is follow-up in years; square shape: 
study- and gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for kidney cancer Figure 7
Meta-analysis of studies for kidney cancer. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gen-
der- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for pancreatic cancer Figure 8
Meta-analysis of studies for pancreatic cancer. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and 
gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for prostate cancer Figure 9
Meta-analysis of studies for prostate cancer. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and 
gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for type II diabetes Figure 10
Meta-analysis of studies for type II diabetes. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and 
gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for hypertension Figure 11
Meta-analysis of studies for hypertension. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gen-
der- specific risk estimates; diamond shape: pooled risk estimates.
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Colorectal cancer
A total of 12 studies were identified for colorectal cancer
(Figures 5 and 6) [19,42,45,54-62]. For men, the pooled
IRRs [95% CI] across categories of WC were 1.88 [1.47–
2.41] for overweight and 2.93 [2.31–3.73] for obesity and
across categories of BMI were 1.51 [1.37–1.67] for over-
weight and 1.95 [1.59–2.39] for obesity. For women, the
pooled IRRs across categories of WC were 1.25 [0.98–
1.59] for overweight and 1.55 [1.27–1.88] for obesity and
those across categories of BMI were 1.45 [1.30–1.62] for
overweight and 1.66 [1.52–1.81] for obesity.
Esophageal cancer
Only 1 study was identified for esophageal cancer [63].
The study found the risk of cancer based on overweight to
be 1.15 [0.97–1.36] and 1.13 [1.02–1.26] for females and
males, respectively. The corresponding risks for obesity
were 1.20 [0.95–1.53] and 1.21 [0.97–1.52].
Kidney cancer
We identified 5 studies meeting the inclusion criteria
relating overweight and obesity to kidney cancer (Figure
7) [42,45,57,64,65]. The pooled IRRs [95% CI] across cat-
egories of BMI for men were 1.40 [1.31–1.49] for over-
weight and 1.82 [1.61–2.05] for obesity. For women the
corresponding risks were 1.82 [1.68–1.98] and 2.64
[2.39–2.90].
Pancreatic cancer
The search identified 6 studies giving information on the
risk of pancreatic cancer attributable to overweight and
obesity (Figure 8) [42,45,66-69]. The pooled IRRs [95%
CI] across categories of BMI for men were 1.28 [0.94–
1.75] for overweight and 2.29 [1.65–3.19] for obesity. For
women the corresponding risks were 1.24 [0.98–1.56]
and 1.60 [1.17–2.20].
Prostate cancer
The search identified 8 studies giving information on the
risk of prostate cancer attributable to overweight and
obesity (Figure 9) [36,42,45,70-74]. The pooled IRRs
[95% CI] across categories of BMI were 1.14 [1.00–1.31]
for overweight and 1.05 [0.85–1.30] for obesity.
Type II diabetes
Nine studies met the inclusion criteria and were included
in the meta-analysis (Figure 10) [19,75-82]. In general,
elevated BMI and WC were significantly associated with
type II diabetes in men and women. The pooled IRRs
[95% CI] across categories of BMI were 2.40 [2.12–2.72]
and 6.74 [5.55–8.19] in men while the corresponding
IRRs in women were 3.92 [3.10–4.97] and 12.41 [9.03–
17.06]. The association between increased WC and type II
diabetes was similar but weaker in comparison with BMI.
Only two studies were included in men. The pooled IRRs
Meta-analysis of studies for stroke Figure 12
Meta-analysis of studies for stroke. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gender- spe-
cific risk estimates; diamond shape: pooled risk estimates.
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[95% CI] across categories of WC were 2.36 [1.76–3.15]
and 5.67 [4.46–7.20] in men and the pooled RR-Ps [95%
CI] based on the same two studies were 2.27 [1.67–3.10]
and 5.13 [3.81–6.90], respectively. The pooled RR-Ps were
more conservative RR estimates and presented in the sum-
mary table (Table 2). The pooled IRRs [95% CI] across cat-
egories of WC were 3.40 [2.42–4.78] and 11.10 [8.23–
14.96] in women.
Hypertension
Four studies met the inclusion criteria and were included
in the meta-analysis (Figure 11) [19,83-85]. The pooled
IRR [95% CI] estimates for hypertension across categories
BMI for men were 1.28 [1.10–1.50] for overweight and
1.84 [1.51–2.24] for obesity. The corresponding figures
for females were 1.65 [1.24–2.19] and 2.42 [1.59–3.67].
The single IRR estimate based on WC for women was 1.38
[1.27–1.51] for overweight and 1.90 [1.77–2.03] for obes-
ity.
Stroke
Seven studies met the inclusion criteria and were included
in the meta-analysis (Figure 12) [86-92]. The pooled RR-
P [95% CI] estimates for stroke across categories BMI for
men were 1.23 [1.13–1.34] for overweight and 1.51
[1.33–1.72] for obesity. The corresponding results for
females were 1.15 [1.00–1.32] and 1.49 [1.27–1.74].
Coronary Artery Disease
Eleven studies were identified with evidence for coronary
artery disease related to obesity (Figures 13 and 14)
[20,21,79,91,93-99]. The pooled RR-P estimates for coro-
nary artery disease across categories of WC were more con-
servative RR estimates for men than the corresponding
IRR estimates and thus were presented in the summary
table (Table 2). The RR-P [95% CI] estimates for WC were
1.41 [1.16–1.72] for overweight and 1.81 [1.45–2.25] for
obesity. The corresponding results for BMI were 1.29
[1.18–1.41] and 1.72 [1.51–1.96]. While the pooled RR-P
estimates based on BMI measurements for women were
generated from 4 studies, the IRR estimates were gener-
ated from 2 different studies with longer follow-up. Thus,
the IRR estimates were the RR estimates for women pre-
sented in the summary table (Table 2). The estimates were
1.80 [1.64–1.98] for overweight and 3.10 [2.81–3.43] for
obesity based on BMI measurements and 1.82 [1.41–
2.36] and 2.69 [2.05–3.53] for WC.
Congestive Heart Failure
Four studies were identified with evidence for congestive
heart failure related to obesity (Figure 15) [91,100-102].
Meta-analysis of studies for coronary artery disease-females Figure 13
Meta-analysis of studies for coronary artery disease-females. *Q-statistic(p-value); F-up is follow-up in years; square 
shape: study- and gender- specific risk estimates; diamond shape: pooled risk estimates.
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The pooled IRR [95% CI] estimates for congestive heart
failure across categories of BMI for men were 1.31 [0.96–
1.79] for overweight and 1.79 [1.24–2.59] for obesity. The
pooled RR-P estimates for females based on 3 studies were
1.27 [0.68–2.37] and 1.78 [1.07–2.95], which were cho-
sen as the RR estimates over the IRR estimates based on 2
studies.
Asthma
Four studies were identified with evidence for asthma
related to obesity (Figure 16) [103-106]. The pooled RR-P
[95% CI] estimates for asthma across categories of BMI for
men were 1.20 [1.08–1.33] for overweight and 1.43
[1.14–1.79] for obese. The corresponding numbers for
females were 1.25 [1.05–1.49] and 1.78 [1.36–2.32].
Chronic back pain
Only 1 study was identified to meet the inclusion criteria
for chronic back pain [107]. The study identified the asso-
ciation for the overweight and obesity with early retire-
ment due to chronic back pain. The study found RR-P
[95% CI] estimates across categories of BMI of chronic
back pain based on overweight to be 1.59 [1.34–1.89] and
for obesity 2.81 [2.27–3.48].
Osteoarthritis
We identified three studies meeting the inclusion criteria
relating overweight and obesity to osteoarthritis (Figure
17) [108-110]. The studies identified the risk of joint
replacement attributable to being overweight and obese.
The pooled IRRs [95% CI] across categories of BMI for
men were 2.76 [2.05–3.70] for overweight and 4.20
[2.76–6.41] for obesity. For women, the RR-P estimates
were more conservative RR estimate and they were 1.80
[1.75–1.85] and 1.96 [1.88–2.04].
Pulmonary embolism
Only 1 study was identified to meet the inclusion criteria
for pulmonary embolism [111]. The study found IRR
[95% CI] across categories of BMI of Pulmonary embo-
lism based on overweight to be 1.91 [1.39–2.64] and for
obesity 3.51 [2.61–4.73].
Gallbladder disease
We identified four studies meeting the inclusion criteria
relating overweight and obesity gallbladder disease (Fig-
ure 18) [59,112-114]. The pooled IRRs [95% CI] across
categories of WC for men were 1.63 [1.42–1.88] for over-
weight and 2.51 [2.16–2.91] for obesity. The correspond-
Meta-analysis of studies for coronary artery disease-males Figure 14
Meta-analysis of studies for coronary artery disease-males. *Q-statistic(p-value); F-up is follow-up in years; square 
shape: study- and gender- specific risk estimates; diamond shape: pooled risk estimates.
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ing pooled RR-Ps were 1.61 [1.40–1.85] and 2.38 [2.06–
2.75]. Thus, the pooled RR-Ps were more conservative RR
estimates and presented in Table 2. Across categories of
BMI, the pooled IRR and RR-P estimates were presented as
the RR estimates in Table 2 and they were 1.09 [0.87–
1.37] for overweight and 1.43 [1.04–1.96] for obesity. For
women only estimates for BMI were identified giving
pooled IRR and RR-P estimates of 1.44 [1.05–1.98] for
overweight and 2.32 [1.17–4.57] for obesity.
Potential publication bias was assessed for post-meno-
pausal breast cancer, endometrial cancer, ovarian cancer,
colorectal cancer, pancreatic cancer for females and pros-
tate cancer. We found some evidence of funnel-plot asym-
metry for obesity in prostate cancer where bigger studies
tended to show stronger positive association than smaller
studies. No evidence of publication bias was found in the
other meta-analyses.
Our sensitivity analyses showed that our results were in
general robust with the following exceptions. For ovarian
cancer, associations for both overweight and obesity were
slightly weaker in US studies compared to European stud-
ies. Similar country differences were found in pancreatic
cancers; in addition, weaker associations were observed in
older population. Studies with shorter follow-up time and
of older population showed slightly weaker association of
obesity with prostate cancer. In coronary artery disease for
females, studies with shorter follow-up showed weaker
associations of both overweight and obese. In coronary
artery disease for males, weaker associations were
observed in US and Canadian studies. Studies of post-
menopausal and senior women on congestive heart fail-
ure showed weaker associations for both overweight and
obesity.
Discussion
We have comprehensively reviewed 20 co-morbidities for
high quality cohort studies which determine risk factors
associated with overweight or obesity. 18 co-morbidities
were identified and meta-analysis was performed where at
least 1 study was found. A summary of the results can be
found in Table 2.
There are a number of alternative meta-analyses with
which we can compare our results. For example, recent
meta-analyses have been reported in diabetes [115,116],
cardiovascular diseases [117], coronary heart disease
[118], hypertension [116], cancer [119], colorectal cancer
[120-122], gallbladder cancer [123], pancreatic cancer
[124], ovarian cancer [125] and asthma [126]. However,
each study uses different definitions of overweight and
obesity, includes varying quality of study designs, uses dif-
ferent methods for meta-analysis and ultimately only
focuses on individual co-morbidities. Hence, the objec-
tive of our study is not only to provide up to date esti-
mates of the risk of all possible co-morbidities
attributable to overweight and obesity, but also to do it
using consistent definitions and methodology.
In assessing whether obesity is related to a given co-mor-
bidity, the occurrence timing of co-morbidities with
respect to exposure of obesity is important in determining
the causal pathway. Therefore, we included only the pro-
Meta-analysis of studies for congestive heart failure Figure 15
Meta-analysis of studies for congestive heart failure. *Q-statistic(p-value); **post-menopause; square shape: study- and 
gender- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for osteoarthritis Figure 17
Meta-analysis of studies for osteoarthritis. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gen-
der- specific risk estimates; diamond shape: pooled risk estimates.
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Meta-analysis of studies for asthma Figure 16
Meta-analysis of studies for asthma. *Q-statistic(p-value); F-up is follow-up in years; square shape: study- and gender- spe-
cific risk estimates; diamond shape: pooled risk estimates.
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spective cohort studies and excluded the cross-sectional
studies and case control studies to minimize the associ-
ated potential biases. In addition, WC measurements were
considered to be the better risk predictor for type II diabe-
tes, hypertension, coronary artery disease, congestive
heart failure, stroke and gallbladder disease [16-24]. In
our studies, the risk for type II diabetes, female hyperten-
sion, coronary artery disease, and male gallbladder dis-
ease were estimated based on WC measurements.
Some limitations are worthy of further consideration.
Firstly, other variables not included in our analysis might
potentially confound our results. Most important is the
exclusion of the level of physical inactivity which is a
known risk factor for some co-morbidities and related to
overweight and obesity [127]. Physical inactivity is often
poorly reported and requiring its inclusion would have
reduced the number of included studies. Secondly, for cer-
tain co-morbidities, we only identified 1 or 2 prospective
cohort studies that adopted the WC measurements as the
risk predictor. Further studies are required to determine
the association between WC and some co-morbidities
before an estimate of the risk can be calculated through a
meta-analysis. Thirdly, given the sizable literature and
that we were searching for non RCT studies for which
search filters are more complex, we determined to use
Medline and Embase as the electronic databases, and
complement the search with checking reference lists and
thorough searching the internet. We did not search other
databases such as CINHAL, HealthSTAR, AMED, and BIO-
SIS. Therefore, bias might have occurred due to our search
strategy. However, given the nature of the studies we are
looking for, i.e., prospective cohort studies with high
quality, we consider our search within Medline and
Embase sufficient. Lastly, due to the small number of
studies for most co-morbidities, assessment of potential
publication bias was infeasible. However, we did not find
evidence of publication bias in those meta-analyses where
the number of studies was relatively large except for pros-
tate cancer.
Conclusion
In conclusion, this study provides a comprehensive esti-
mate of the incidence of 18 co-morbidities attributable to
overweight and obesity using standardized and consistent
definitions and methodologies. Our findings confirm that
overweight and obesity carry a profound health burden
and will have a significant impact on health expenditures.
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Table 2: Relative co-morbidity risks related to being overweight or obese
Co-morbidity Measure Overweight Obesity
Male Female Male Female
Type II Diabetes* BMI 2.40 (2.12–2.72) 3.92 (3.10–4.97) 6.74 (5.55–8.19) 12.41 (9.03–17.06)
WC 2.27 (1.67–3.10)† 3.40 (2.42–4.78) 5.13 (3.81–6.90)† 11.10 (8.23–14.96)
Cancer
Breast, Postmenopausal BMI - 1.08 (1.03–1.14) - 1.13 (1.05–1.22)
Colorectal BMI 1.51 (1.37–1.67) 1.45 (1.30–1.62) 1.95 (1.59–2.39) 1.66 (1.52–1.81)
Endometrial BMI - 1.53 (1.45–1.61) - 3.22 (2.91–3.56)
Esophageal BMI 1.13 (1.02–1.26) 1.15 (0.97–1.36) 1.21 (0.97–1.52) 1.20 (0.95–1.53)
Kidney BMI 1.40 (1.31–1.49) 1.82 (1.68–1.98) 1.82 (1.61–2.05) 2.64 (2.39–2.90)
Ovarian BMI - 1.18 (1.12–1.23) - 1.28 (1.20–1.36)
Pancreatic BMI 1.28 (0.94–1.75) 1.24 (0.98–1.56) 2.29 (1.65–3.19) 1.60 (1.17–2.20)
Prostate BMI 1.14 (1.00–1.31) - 1.05 (0.85–1.30) -
Cardiovascular Diseases
Hypertension* BMI 1.28 (1.10–1.50) 1.65 (1.24–2.19) 1.84 (1.51–2.24) 2.42 (1.59–3.67)
WC NA 1.38 (1.27–1.51) NA 1.90 (1.77–2.03)
Coronary Artery Disease* BMI 1.29 (1.18–1.41)† 1.80 (1.64–1.98) 1.72 (1.51–1.96)† 3.10 (2.81–3.43)
WC 1.41 (1.16–1.72)† 1.82 (1.41–2.36) 1.81 (1.45–2.25)† 2.69 (2.05–3.53)
Congestive Heart Failure* BMI 1.31 (0.96–1.79) 1.27 (0.68–2.37)† 1.79 (1.24–2.59) 1.78 (1.07–2.95)†
Pulmonary Embolism BMI 1.91 (1.39–2.64) 1.91 (1.39–2.64) 3.51 (2.61–4.73) 3.51 (2.61–4.73)
Stroke* BMI 1.23 (1.13–1.34)† 1.15 (1.00–1.32)† 1.51 (1.33–1.72)† 1.49 (1.27–1.74)†
Other
Asthma BMI 1.20 (1.08–1.33)† 1.25 (1.05–1.49)† 1.43 (1.14–1.79)† 1.78 (1.36–2.32)†
Gallbladder Disease* BMI 1.09 (0.87–1.37)‡ 1.44 (1.05–1.98)‡ 1.43 (1.04–1.96)‡ 2.32 (1.17–4.57)‡
WC 1.61 (1.40–1.85)† NA 2.38 (2.06–2.75)† NA
Osteoarthritis BMI 2.76 (2.05–3.70) 1.80 (1.75–1.85)† 4.20 (2.76–6.41) 1.96 (1.88–2.04)†
Chronic Back Pain BMI 1.59 (1.34–1.89)† 1.59 (1.34–1.89)† 2.81 (2.27–3.48)† 2.81 (2.27–3.48)†BMC Public Health 2009, 9:88 http://www.biomedcentral.com/1471-2458/9/88
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